• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Invivyd Launches "Antibodies for Any Body" in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health

    4/7/26 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IVVD alert in real time by email
    • National education campaign aims to educate Americans about antibodies and their role in immune health
    • Campaign centerpiece, AntibodiesforAnyBody.com, offers an interactive immune health wellness assessment to empower people to better understand the relationship between their daily habits and immune health and wellness



    NEW HAVEN, Conn., April 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the launch of Antibodies for Any Body, a national education campaign designed to elevate public understanding of antibodies, one of the most important parts of the immune system, and their role in protecting against disease. The campaign launches in collaboration with renowned ski champion Lindsey Vonn, whose career has been defined by training with intention, overcoming challenges, and caring for her body from the inside out.

    As part of the launch, Invivyd unveiled AntibodiesforAnyBody.com, a new online education resource offering clear, accessible information about immune health and how antibodies function as part of the body's natural defense system. The site also includes the Antibodies for Any Body Wellness Assessment, an interactive learning tool designed to help individuals understand how certain lifestyle habits may help support their immune system, including antibody production and function.

    "People want to feel more confident about their health – especially at a moment when prevention of infectious disease is of immense national interest," said Marc Elia, Chairman of Invivyd's Board of Directors. "Antibodies play a key role in the immune system, but many people may not be familiar with what they are or how everyday habits can influence their production and function. Antibodies for Any Body was created to bring clarity to the conversation in a way that is both accessible and empowering. Lindsey brings a rare combination of relatability, discipline, and authenticity, and we're proud to have her as our partner as we elevate understanding of the links between immune health, antibodies, and wellness."

    Antibodies are protective proteins produced by the immune system. Their job is to recognize and help remove substances that do not belong in the body, such as germs or toxins. Common healthy habits – like getting enough sleep, proper nutrition, and regular physical activity – all ladder up to a healthy lifestyle, which supports immune function, including antibody protection.

    "My entire career has been about understanding what my body needs to perform at its best – training hard, recovering smart, and paying attention to the things you can't always see," said Lindsey Vonn. "Over time, I've learned that real strength starts with how your body protects you from the inside. Antibodies play a big role in helping keep us healthy, and when you learn what they do and how they work, you may realize you have more control over your health than you might think. I partnered with Invivyd to help build the connection between antibodies and wellness and to show that anybody can take steps to optimize their immune system, including antibody protection."

    While the campaign partnership began before her recent crash and subsequent recovery journey, the core message of the initiative, empowering individuals to understand and support their immune health, remains central to Vonn's wellness philosophy.

    To learn more about how antibodies work and explore simple ways to support immune health, visit AntibodiesforAnyBody.com and take the interactive Antibodies for Any Body Wellness Assessment. Talk to your doctor about which healthy habits are right for you.

    About Antibodies for Any Body

    Antibodies for Any Body is a national education campaign designed to elevate public understanding of the immune system and explain the role antibodies play in keeping the body healthy. Visit AntibodiesforAnyBody.com to access information and resources and take the Antibodies for Any Body Wellness Assessment to learn more about your health.

    About Invivyd

    Invivyd, Inc. (NASDAQ:IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. Visit https://invivyd.com/ to learn more.

    Trademarks are the property of their respective owners.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "could," "expects," "estimates," "intends," "plans," "potential," "predicts," "projects," and "future" or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the expectations regarding the company's partnership with Lindsey Vonn; expectations related to the company's Antibodies for Any Body national educational campaign and Lindsey Vonn's role as part of this initiative; the company's devotion to delivering protection from serious viral infectious diseases; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company's forward-looking statements and you should not place undue reliance on the company's forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the execution and results of the company's Antibodies for Any Body national education campaign; whether the anticipated benefits of the company's partnership with Lindsey Vonn are realized; the timing, progress, and results of the company's discovery, preclinical, and clinical development activities; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; unexpected safety or efficacy data observed during preclinical studies or clinical trials; changes in the regulatory environment; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways; changes in expected or existing competition; the company's reliance on third parties; macroeconomic and political uncertainties; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (SEC), and in the company's other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.

    This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

    Contacts:

    Media Relations

    (781) 208-0160

    [email protected]

    Investor Relations

    (781) 208-1747

    [email protected]



    Primary Logo

    Get the next $IVVD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IVVD

    DatePrice TargetRatingAnalyst
    12/22/2025$10.00Buy
    BTIG Research
    11/25/2025Buy → Hold
    D. Boral Capital
    10/6/2025$10.00Overweight
    Cantor Fitzgerald
    4/5/2024$9.00Neutral → Buy
    Guggenheim
    3/26/2024$4.00 → $10.00Equal-Weight → Overweight
    Morgan Stanley
    12/19/2023$1.00 → $4.00Underweight → Equal-Weight
    Morgan Stanley
    5/1/2023$5.00Buy
    H.C. Wainwright
    More analyst ratings

    $IVVD
    SEC Filings

    View All

    SEC Form DEFA14A filed by Invivyd Inc.

    DEFA14A - Invivyd, Inc. (0001832038) (Filer)

    4/6/26 4:25:18 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Invivyd Inc.

    DEF 14A - Invivyd, Inc. (0001832038) (Filer)

    4/6/26 4:19:03 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Invivyd Inc.

    10-K - Invivyd, Inc. (0001832038) (Filer)

    3/5/26 7:20:57 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Invivyd Launches "Antibodies for Any Body" in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health

    National education campaign aims to educate Americans about antibodies and their role in immune healthCampaign centerpiece, AntibodiesforAnyBody.com, offers an interactive immune health wellness assessment to empower people to better understand the relationship between their daily habits and immune health and wellness NEW HAVEN, Conn., April 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the launch of Antibodies for Any Body, a national education campaign designed to elevate public understanding of antibodies, one of the most important parts of the immune system, and their role in protecting against disease. The campaign launches in collaboration with renowned sk

    4/7/26 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEW HAVEN, Conn., April 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that on April 1, 2026, Invivyd granted 16 newly hired non-executive employees options to purchase an aggregate of 1,083,750 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan. The options have a per share exercise price of $1.33, representing the closing price of Invivyd's common stock on the grant date. Each option vests over four years, with 25% of the shares subject to such option vesting on the first

    4/6/26 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Announces Presentation at the World Vaccine Congress Washington

    Chief Scientific Officer, Robert Allen, Ph.D., presented as part of the "Antibodies for Infectious Disease Workshop" at the World Vaccine Congress WashingtonPresentation titled "Developing mAb Therapies that Keep Pace with Rapidly Evolving Viral Threats"Invivyd commends World Vaccine Congress Washington for hosting antibodies workshop and recognizing prophylaxis should include more than one modality NEW HAVEN, Conn., March 30, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that Robert Allen, Ph.D., Chief Scientific Officer at Invivyd, presented as part of the Antibodies for Infectious Disease Workshop at the World Vaccine Congress Washington. Dr. Allen's presentation

    3/30/26 4:05:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Invivyd with a new price target

    BTIG Research initiated coverage of Invivyd with a rating of Buy and set a new price target of $10.00

    12/22/25 8:39:25 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd downgraded by D. Boral Capital

    D. Boral Capital downgraded Invivyd from Buy to Hold

    11/25/25 8:11:06 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Invivyd with a new price target

    Cantor Fitzgerald initiated coverage of Invivyd with a rating of Overweight and set a new price target of $10.00

    10/6/25 8:27:43 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Allen Robert D. Iii converted options into 99,000 shares and sold $58,600 worth of shares (37,581 units at $1.56), increasing direct ownership by 116% to 114,487 units (SEC Form 4)

    4 - Invivyd, Inc. (0001832038) (Issuer)

    2/18/26 8:56:34 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Human Resources Officer Green Julie converted options into 99,000 shares and sold $63,350 worth of shares (40,627 units at $1.56), increasing direct ownership by 118% to 107,717 units (SEC Form 4)

    4 - Invivyd, Inc. (0001832038) (Issuer)

    2/18/26 8:51:23 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Duke William E. converted options into 99,000 shares and sold $63,350 worth of shares (40,627 units at $1.56), increasing direct ownership by 118% to 107,717 units (SEC Form 4)

    4 - Invivyd, Inc. (0001832038) (Issuer)

    2/18/26 8:49:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mclaughlin Kevin F bought $125,000 worth of shares (50,000 units at $2.50) (SEC Form 4)

    4 - Invivyd, Inc. (0001832038) (Issuer)

    11/20/25 4:22:07 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Invivyd Inc.

    SC 13D/A - Invivyd, Inc. (0001832038) (Subject)

    12/12/24 4:39:09 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

    SC 13G/A - Invivyd, Inc. (0001832038) (Subject)

    11/14/24 4:30:58 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

    SC 13G/A - Invivyd, Inc. (0001832038) (Subject)

    11/14/24 9:16:35 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Leadership Updates

    Live Leadership Updates

    View All

    Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

    Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital, Dr. Mina strengthens Invivyd's medical leadership Dr. Mina's research at Harvard focused on antibodies, vaccines, and infectious diseases with special expertise in COVID-19, measles, and other diseases, and will be a significant asset to Invivyd and the advancement of its pipelineWith more than 100 scientific publications and 10,000 citations, as well as hundreds of popular press interviews and op-eds, Dr. Mina is an expert in conducting research and conveying its meaning and impact to healthc

    3/5/26 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

    NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (NASDAQ:IVVD) is hosting the previously announced live webcast to present an overview of the company's REVOLUTION clinical program, Invivyd's development program for VYD2311, a vaccine-alternative monoclonal antibody candidate for the prevention of COVID. The session will feature key members of the Invivyd team. WHEN: Thursday, October 30, 2025, at 8:30 a.m. ET WHERE: Listeners are advised to join the webcast via the following link 15 minutes prior to the start time. A replay of the webcast will be available via the investor relations section of the company's website approximately two hours after the conclusion of

    10/28/25 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

    NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 2013. "We are happy to have Dr. Bolno join our Board at this critical moment while we transition toward a future focused on helping large populations avoid becoming ill from major viral infectious diseases," said Marc Elia, Chairman of the Board of Invivyd. "Dr. Bolno's extensive experience in leading Wave Life Sciences through rapid pipeline developm

    9/24/25 4:01:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Financials

    Live finance-specific insights

    View All

    Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

    Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025DECLARATION trial on track with full enrollment achievedDECLARATION trial Independent Data Monitoring Committee (IDMC) prespecified review of unblinded VYD2311 safety data resulted in IDMC re

    3/5/26 7:03:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

    NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 5, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide a corporate update. Interested parties may join the live webcast by visiting this link. Analysts wishing to participate in the question-and-answer session should use this link. Those who plan on participating are advised to join 15 minutes prior to the start time. A recording of the webcast will be available on the company's investor rel

    3/2/26 4:10:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

    NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 6, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide a corporate update. Interested parties may join the live webcast by visiting this link and are advised to log in approximately 15 minutes prior to the start of the call. A recording of the webcast will be available on the company's investor relations website shortly after the event. About Invivyd Invivyd, Inc. (NASDAQ:IVVD) is a biopharmaceutical c

    11/3/25 4:01:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care